Navigation Links
Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity
Date:1/9/2008

INDIANAPOLIS, Jan. 9 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that a paper published in Cancer Research (2008; Vol. 68, Issue 1: 206-215) reports that SF1126, the company's lead product candidate, exhibits antitumor and antiangiogenic activity.

The paper, entitled "A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity," is based on preclinical studies conducted by Semafore and collaborators at Children's Healthcare of Atlanta, Emory University School of Medicine, and M.D. Anderson Cancer Center. Phosphoinositide 3-kinase (PI3K) is a powerful pathway and an emerging cancer target for inhibition. In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo. In addition, SF1126 displayed potent antitumor and antiangiogenic activity in vivo, in mouse models, against a variety of human cancer cell types, including prostate, breast, neuroblastoma, and glioblastoma.

SF1126 differs from other known PI3K inhibitors in that it has a homing feature designed to localize more drug in the tumor compartment. Based on the studies reported in the paper, SF1126 also significantly enhanced the activity of docetaxel in a combination regiment in a prostate cancer model.

"The data further support our belief that SF1126 is a viable pan PI3K inhibitor as we continue Phase I clinical trials," said Ed Jacobs, Semafore's president and chief executive officer. "SF1126 continues to support the paradigm shift in cancer treatment that will see the application of highly targeted therapeutic drugs that inhibit the powerful PI3K pathway."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major fact
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
4. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
5. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
6. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
9. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
10. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
11. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in Boston.  The public is welcome to ... the Array BioPharma website.Event: Wells Fargo Securities Healthcare ... September 10, 2015Time:  , 10:20 a.m. Eastern Time ...
(Date:9/2/2015)... 2, 2015 About Chronic Lymphocytic Leukemia ... characterized by increased production of lymphocytes. It has been ... it can spread to other parts of the body. ... of the slow buildup of the cancerous cells. During ... the spleen, liver, and lymph nodes. The course of ...
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye, today announced that its Board of Directors has ... Mr. Wall was formerly the General Counsel ... firm, for more than nine years. Mr. Wall is currently ... the Corporate Governance Committee and member of the Audit Committee, ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... Md., Nov. 28, 2011 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today that ... present at the Piper Jaffray 23rd Annual Healthcare Conference ... Richman will also be available to participate in one-on-one ...
... Conn., Nov. 28, 2011 Gaylord Sleep Medicine now ... their Glastonbury, Guilford, North Haven and Trumbull locations. ... new Sleep Apnea Management program has expanded to offer ... patient needs. Originally designed to improve PAP compliance, the ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2Gaylord Sleep Medicine Expands Sleep Apnea Management Program 2
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
(Date:9/3/2015)... ... September 03, 2015 , ... Fashion designer Kim (29 ... of the most recent episode of the hit ABC series “Extreme Weight Loss” ... image of her industry. She provided herself with the motivation to transform when she ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... by the Military Officers Association of America (MOAA) and Wounded Warrior Project® ... Caring For Our Own,” expert panelists will lead interactive discussions on the ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3
... , DES MOINES, Iowa, July 10 The "Help is ... the week of July 13 - 16 at various cities ... on programs that provide prescription medicines for free or nearly ... compared to 3.7 percent a year ago, the Partnership for ...
... , NEW YORK, July 10, 2009 Forest ... its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, ... that they have entered into a settlement ... a reference that includes its 100% subsidiaries) and ...
... Va., July 10 The American Physical Therapy Association (APTA) is ... to be properly assessed and fitted by a physical therapist to ... published in the Journal of the American Geriatrics Society ... emergency rooms each year due to falls from improper use and ...
... DENVER, July 10 Cochlear Americas announced today that ... the Cochlear(TM) Baha(R) BP100 Sound Processor, the industry,s first ... an excellent choice for many children and adults with ... deafness. , , The Baha BP100 improves ...
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... damage during play, study finds , FRIDAY, July 10 ... before the season starts may predict the player,s chance ... , Such knowledge could help the pitcher avert ... said. , A five-year study of 144 professional baseball ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 4Health News:Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation 2Health News:Physical Therapists Say Proper Fit and Use of Walkers and Canes Can Prevent Fall-Related Injuries in Elderly 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 3Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Rad-9™...
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
Halogen-free immersion oil based on ester oil....
Medicine Products: